Biomarkers of vascular disease in scleroderma

Rheumatology

Volumn 47, Issue SUPPL. 5, 2009, Pages

  Hummers, L K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biomarkers; Diffusing capacity for carbon monoxide; N terminal pro BNP; Pulmonary hypertension; Scleroderma

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; DIURETIC AGENT; DNA TOPOISOMERASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; INTERCELLULAR ADHESION MOLECULE 1; THROMBOMODULIN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEART RIGHT VENTRICLE FAILURE; HUMAN; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 69949168097     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken281     Document Type: Conference Paper

References (10)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
2. Hesselstrand R, Ekman R, Eskilsson J, Isaksson A, Scheja A, Ohlin AK, Akesson A. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology 2005;44:366-71.
3. Distler O, Del Rosso A, Giacomelli R et al. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4:R11.
4. Mittag M, Beckheinrich P, Haustein UF. Systemic sclerosis-related Raynaud's phenomenon: Effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001;81:294-7.
5. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
6. Allanore Y, Borderie D, Avouac D. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.
7. Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: Assessing the response to therapy. Clin Chest Med 2007;28:75-89, viii.
8. Williamson DJ, Wallman LL, Jones R. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000;102:411-8.
9. Sfikakis PP, Papamichael C, Stamatelopoulos KS. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007;56:985-93.
10. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006;98:525-9.